PD-L1抑制剂在非小细胞肺癌中的应用

doi:10.3760/cma.j.cn371439-20210121-00018

摘要/Abstract

摘要：

非小细胞肺癌(NSCLC)患者的治疗方式多样,除放疗、化疗、靶向治疗外,免疫检查点抑制剂也取得突破性进展,尤其是程序性细胞死亡受体-1(PD-1)及其配体(PD-L1)抑制剂改善了NSCLC患者的生存,部分被美国食品和药物管理局批准为一线用药。目前常用的PD-L1抑制剂有阿特珠单抗、度伐利尤单抗和阿维鲁单抗,联合疗法包括联合化疗、血管内皮生长因子抑制剂、分子靶向治疗和免疫治疗。

关键词: 肺肿瘤, 免疫疗法, PD-L1

Abstract:

Patients with non-small cell lung cancer (NSCLC) are treated in a variety of ways. In addition to radiotherapy, chemotherapy and targeted therapy, breakthroughs have been made in immune checkpoint inhibitors, in particular, programmed cell death 1 (PD-1) and its ligand (PD-L1) inhibitors have achieved survival benefits for NSCLC patients, and some of them have been approved as first-line drugs by the US Food and Drug Administration. Currently, commonly used PD-L1 inhibitors are atezolizumab, durvalumab and avelumab. Combination therapies include combination with chemotherapy, anti-vascular endothelial growth factor drugs, molecular targeted therapy and immunotherapy.

Key words: Lung neoplasms, Immunotherapy, PD-L1

谢红霞, 左金辉, 廖冬颖, 邓仁芬, 姚杨, 贾英杰, 李小江, 孔凡铭. PD-L1抑制剂在非小细胞肺癌中的应用[J]. 国际肿瘤学杂志, 2022, 49(2): 111-115.

Xie Hongxia, Zuo Jinhui, Liao Dongying, Deng Renfen, Yao Yang, Jia Yingjie, Li Xiaojiang, Kong Fanming. Application of PD-L1 inhibitors in the treatment of non-small cell lung cancer[J]. Journal of International Oncology, 2022, 49(2): 111-115.

参考文献 28

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660. doi: 10.3322/caac.21660
[2]	US Preventive Services Task Force, Krist AH, Davidson KW, et al. Screening for lung cancer: US preventive services task force recommendation statement[J]. JAMA, 2021, 325(10): 962-970. DOI: 10.1001/jama.2021.1117. doi: 10.1001/jama.2021.1117 pmid: 33687470
[3]	Deng R, Bumbaca D, Pastuskovas CV, et al. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor[J]. MAbs, 2016, 8(3): 593-603. DOI: 10.1080/19420862.2015.1136043. doi: 10.1080/19420862.2015.1136043
[4]	Kwiatkowski DJ, Rusch VW, Chaft JE, et al. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): interim analysis and biomarker data from a multicenter study (LCMC3)[EB/OL]. [2019-06-01]. https://meetinglibrary.asco.org/record/173482/abstract.
[5]	Shu CA, Gainor JF, Awad MM, et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2020, 21(6): 786-795. DOI: 10.1016/S1470-2045(20)30140-6. doi: 10.1016/S1470-2045(20)30140-6
[6]	Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC[J]. N Engl J Med, 2020, 383(14): 1328-1339. DOI: 10.1056/NEJMoa1917346. doi: 10.1056/NEJMoa1917346
[7]	Landreneau JP, Shurin MR, Agassandian MV, et al. Immunological mechanisms of low and ultra-low dose cancer chemotherapy[J]. Cancer Microenviron, 2015, 8(2): 57-64. DOI: 10.1007/s12307-013-0141-3. doi: 10.1007/s12307-013-0141-3
[8]	Champiat S, Ileana E, Giaccone G, et al. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC[J]. J Thorac Oncol, 2014, 9(2): 144-153. DOI: 10.1097/JTO.00000000000-00074. doi: 10.1097/JTO.00000000000-00074
[9]	West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, rando-mised, open-label, phase 3 trial[J]. Lancet Oncol, 2019, 20(7): 924-937. DOI: 10.1016/S1470-2045(19)30167-6. doi: 10.1016/S1470-2045(19)30167-6
[10]	Jotte R, Cappuzzo F, Vynnychenko I, et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase Ⅲ trial[J]. J Thorac Oncol, 2020, 15(8): 1351-1360. DOI: 10.1016/j.jtho.2020.03.028. doi: 10.1016/j.jtho.2020.03.028
[11]	Nishio M, Barlesi F, West H, et al. Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial[J]. J Thorac Oncol, 2021, 16(4): 653-664. DOI: 10.1016/j.jtho.2020.11.025. doi: 10.1016/j.jtho.2020.11.025
[12]	Hegde PS, Wallin JJ, Mancao C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics[J]. Semin Cancer Biol, 2018, 52(Pt 2): 117-124. DOI: 10.1016/j.semcancer.2017.12.002. doi: 10.1016/j.semcancer.2017.12.002
[13]	Chen DS, Hurwitz H. Combinations of bevacizumab with cancer immunotherapy[J]. Cancer J, 2018, 24(4): 193-204. DOI: 10.1097/PPO.0000000000000327. doi: 10.1097/PPO.0000000000000327
[14]	Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC[J]. N Engl J Med, 2018, 378(24): 2288-2301. DOI: 10.1056/NEJMoa1716948. doi: 10.1056/NEJMoa1716948
[15]	Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizu-mab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial[J]. Lancet Respir Med, 2019, 7(5): 387-401. DOI: 10.1016/S2213-2600(19)30084-0. doi: 10.1016/S2213-2600(19)30084-0
[16]	Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition[J]. Am J Clin Oncol, 2016, 39(1): 98-106. DOI: 10.1097/COC.000000000-0000239. doi: 10.1097/COC.000000000-0000239
[17]	白馨雅, 张金梦, 孙洋, 等. 免疫检查点抑制剂在晚期非小细胞肺癌综合治疗中的应用[J]. 国际肿瘤学杂志, 2019, 46(8): 500-504. DOI: 10.3760/cma.j.issn.1673-422X.2019.08.012. doi: 10.3760/cma.j.issn.1673-422X.2019.08.012
[18]	Rizvi NA, Cho BC, Reinmuth N, et al. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial[J]. JAMA Oncol, 2020, 6(5): 661-674. DOI: 10.1001/jamaoncol.2020.0237. doi: 10.1001/jamaoncol.2020.0237
[19]	AstraZeneca. Imfinzi and tremelimumab with chemotherapy demonstrated overall survival benefit in POSEIDON trial for 1st-line stage Ⅳ non-small cell lung cancer[EB/OL]. [2021-05-07]. https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-and-tremelimumab-showed-survival-in-poseidon.html.
[20]	Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage Ⅲ non-small-cell lung cancer[J]. N Engl J Med, 2017, 377(20): 1919-1929. DOI: 10.1056/NEJMoa1709937. doi: 10.1056/NEJMoa1709937
[21]	Gray JE, Villegas A, Daniel D, et al. Three-year overall survival with durvalumab after chemoradiotherapy in stage Ⅲ NSCLC-update from PACIFIC[J]. J Thorac Oncol, 2020, 15(2): 288-293. DOI: 10.1016/j.jtho.2019.10.002. doi: 10.1016/j.jtho.2019.10.002
[22]	Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial[J]. Lancet, 2016, 387(10030): 1837-1846. DOI: 10.1016/S0140-6736(16)00587-0. doi: 10.1016/S0140-6736(16)00587-0 pmid: 26970723
[23]	Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial[J]. Lancet, 2017, 389(10066): 255-265. DOI: 10.1016/S0140-6736(16)32517-X. doi: S0140-6736(16)32517-X pmid: 27979383
[24]	Mazieres J, Rittmeyer A, Gadgeel S, et al. Atezolizumab versus docetaxel in pretreated patients with NSCLC: final results from the randomized phase 2 POPLAR and phase 3 OAK clinical trials[J]. J Thorac Oncol, 2021, 16(1): 140-150. DOI: 10.1016/j.jtho.2020.09.022. doi: 10.1016/j.jtho.2020.09.022 pmid: 33166718
[25]	Barlesi F, Vansteenkiste J, Spigel D, et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study[J]. Lancet Oncol, 2018, 19(11): 1468-1479. DOI: 10.1016/S1470-2045(18)30673-9. doi: 10.1016/S1470-2045(18)30673-9
[26]	Garassino MC, Cho BC, Kim JH, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (Atlantic): an open-label, single-arm, phase 2 study[J]. Lancet Oncol, 2018, 19(4): 521-536. DOI: 10.1016/S1470-2045(18)30144-X. doi: S1470-2045(18)30144-X pmid: 29545095
[27]	Garassino MC, Cho BC, Kim JH, et al. Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: the phase Ⅱ Atlantic study[J]. Lung Cancer, 2020, 147:137-142. DOI: 10.1016/j.lungcan.2020.06.032. doi: S0169-5002(20)30506-7 pmid: 32702570
[28]	Planchard D, Reinmuth N, Orlov S, et al. ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer[J]. Ann Oncol, 2020, 31(5): 609-618. DOI: 10.1016/j.annonc.2020.02.006. doi: S0923-7534(20)36041-5 pmid: 32201234